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OBJECTIVE—Costimulation blockade has emerged as a selec-
tive nontoxic maintenance therapy in transplantation. However,
these drugs must be combined with other immunomodulatory
agents to ensure long-term graft survival.
RESEARCH DESIGN AND METHODS—Recent work has
demonstrated that caspase inhibitor therapy (EP1013) prevents
engraftment phase islet loss and markedly reduces the islet mass
required to reverse diabetes. The “danger” hypothesis suggests
that reduction in graft apoptosis should reduce the threshold for
immunosuppression and increase the possibility for tolerance
induction. Thus, the impact of combination of EP1013 treatment
with costimulation blockade (CTLA4-Ig) was investigated in this
study.
RESULTS—Islet allografts were completed in fully major histo-
compatibility complex (MHC)-mismatched mice (Balb/C to B6).
When animals received vehicle or EP1013, there was no differ-
ence in graft survival. CTLA4-Ig resulted in prolonged graft
survival in 40% of the animals, whereas EP1013CLTA4-Ig
resulted in a signiﬁcant increase in graft survival (91% 180 days;
P  0.01). Ex vivo analysis revealed that animals receiving
EP1013 or EP1013CTLA4-Ig had a reduced frequency of allo-
reactive interferon (IFN)-–secreting T-cells and an increased
frequency of intragraft Foxp3
 Treg cells. Alloantibody assays
indicated that treatment with EP1013 or CTLA4-Ig prevented
allosensitization.
CONCLUSIONS—This study suggests that addition of caspase
inhibitor therapy to costimulation blockade will improve clinical
transplantation by minimizing immune stimulation and thus
reduce the requirement for long-term immunosuppressive ther-
apy. The approach also prevents allosensitization, which may be
an important component of chronic graft loss in clinical
transplantation. Diabetes 59:1469–1477, 2010
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trategies aimed at minimizing donor organ injury
and the induction of immunological tolerance
have been a major area of research in transplan-
tation over the past decade. One of the most
promising new immunosuppressive agents involves co-
stimulatory blockade, which prevents signal 2 during
T-cell activation, resulting in T-cell anergy. Belatacept, a
high-afﬁnity version of CTLA4-Ig, the most widely studied
costimulatory blockade agent, is currently in phase III
studies in renal transplantation. Whereas CTLA4-Ig has
been shown to be an effective immunomodulatory agent in
preclinical animal models, long-term graft survival has
only been achieved when this agent is combined with
other immunomodulatory agents, such as anti-CD154 or
sirolimus (1–3). In clinical renal transplantation, belata-
cept has proven to be as effective as cyclosporine for
maintenance immunosuppression, with a reduced rate of
chronic allograft nephropathy (4). Taken together, these
data suggest that costimulation blockade maintenance
therapy will minimize end organ damage, but further
development of combination strategies must be under-
taken to further minimize post-transplant immunosuppres-
sion regimens or induce tolerance.
Over the past several years, our group has explored
caspase inhibitor therapies as a means to prevent early
graft loss in islet transplantation. During the procurement,
preservation, implantation, and reperfusion of an allograft,
considerable damage occurs, resulting in intragraft inﬂam-
mation and shedding of donor antigen. In the setting of
islet transplantation, this effect is profound, since an
estimated 60% or more of the implanted tissue fails to
engraft after portal infusion (5). As a result, islets derived
from at least two cadaveric organ donors are generally
required to achieve insulin independence (10,000 islet
equivalents/kg recipient body weight) (6). The majority of
these transplanted islets never become functional and are
lost via apoptosis (7). In an effort to prevent postimplan-
tation graft loss, we used synthetic peptidyl pan caspase
inhibitors (zVAD-FMK and EP1013 [zVD-FMK]) as a tran-
sient systemic therapy in marginal islet mass models using
both syngeneic rodent islet grafts and human islets trans-
planted into immunodeﬁcient chemically diabetic mice
(8,9). These small molecule therapies bind to the active
site of both initiation and effector caspases, thereby pre-
venting apoptosis resulting from extrinsic signals (i.e.,
cytokines, Fas pathway) and intrinsic signals (i.e., hyp-
oxia, nutrient deprivation). In these studies, our data
demonstrated that the caspase inhibitors are required as a
post-transplant therapy for up to 5 days to maximize islet
graft survival during the engraftment period. Using both
mouse and human islet grafts in mice, caspase inhibitor
therapy for only 5 days post-transplant resulted in a
majority of animals achieving insulin independence, with a
70–80% reduction in islet mass. In addition, our data
demonstrated that a brief period of caspase inhibitor
therapy can stabilize a marginal mass islet graft, prevent-
ing metabolic burnout over time post-transplant (9).
In these studies, the effect of caspase inhibitor therapy
during islet engraftment was examined in animal models
that do not generate an immune response to the graft.
However, our data have shown that caspase inhibitor
therapy prevents islet cell death post-transplant, which
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ients that receive this therapy. In the context of allograft
rejection, the overall health of the donor tissue has been
implicated in directing the immunological behavior of the
graft recipient. Data investigating the “danger” hypothesis
suggests that death of donor tissue and its associated
inﬂammatory response sends out warning signals to the
immune system, resulting in activation of alloreactive
T-cells (10–12). Conversely, when a graft is allowed to
“heal in” before immune reconstitution, there are less
“danger signals” being transmitted, and as such, the im-
mune system is less activated and more likely to become
tolerant to the allograft (10–12). Although this hypothesis
has never been challenged in the face of an apoptosis-
resistant graft (versus a healed-in graft), the model sug-
gests that marked reduction in graft apoptosis should
result in lower requirements for immunosuppression and a
greater possibility for tolerance induction. For these rea-
sons, the effect of combination therapy using CTLA4-Ig
and EP1013 in murine islet allograft transplantation was
explored in the present study.
RESEARCH DESIGNS AND METHODS
Animals. Mice were obtained from Jackson Labs (Bar Harbor, ME) and
housed under speciﬁc pathogen-free conditions. Ethical approval was ob-
tained from the animal welfare committee at the University of Alberta, and all
animal care was in accordance with the guidelines of the Canadian Council on
Animal Care.
Caspase inhibitor therapy. EP1013 was obtained from Epicept Corporation
(San Diego, CA), and CTLA4-Ig was obtained from Bioexpress (West Lebanon,
NH). Stock preparations of EP1013 were prepared in DMSO and diluted into
sterile saline.
Islet transplantation studies. Mouse islets were isolated from Balb/C
(H-2d) and C3H (H-2k) donors using established methods (13). Streptozotocin
(Sigma-Aldrich, Canada, Mississauga, ON) was used to induce diabetes in
C57BL/6 (“B6”, H-2b) recipients (250 mg/kg i.p.). Before transplantation,
mouse islet preparations were incubated in medium containing caspase
inhibitor (EP1013 at 100 mol/l in Dulbecco’s modiﬁed Eagle’s medium with
10% FCS, Invitrogen Canada) or vehicle for 2 h. Transplant recipients were
treated with either vehicle solution (DMSO in sterile saline) or caspase
inhibitor (3 mg/kg s.c., days 0–10). CTLA4-Ig was administered on days 0, 2, 4,
and 6 post-transplant (0.25 mg i.p.) (14). Animals were monitored three times
per week, and two consecutive blood glucose values 18 mmol/l was
considered to be evidence of rejection. Euglycemic animals from each cohort
were selected randomly, and the graft-bearing kidney was removed to
establish that the islet graft was functional, as determined by a return to
hyperglycemia postnephrectomy (18 mmol/l).
Immunoﬂuorescence. Cryostat sections (10 m) of islet grafts were stained
as previously described (15). Rat anti-mouse CD4 (clone GK1.5), rat anti-
mouse CD8 (clone 53-6.7), rat-anti-mouse Foxp3 (clone FJK-16s), and poly-
clonal guinea pig anti-insulin were used. All slides were photographed at
100–200 magniﬁcation, and the total number of ﬂuorescein isothiocya-
nate (FITC)
 cells per section were quantiﬁed from N  4–5 animals per
treatment group (minimum three sections per animal analyzed).
Alloantibody assays. Serum was harvested from treated animals and stored
until the completion of the study for bulk analysis. Alloantibody levels were
determined using the indirect cellular enzyme-linked immunosorbent assay
(ELISA) method described by Fan et al. (16).
Mixed lymphocyte reactions and ELISPOT assays. Animals were killed at
11 days post-transplant, and splenocytes were harvested and puriﬁed using
Lympholyte-M (Cedarlane). Donor-type Balb/C splenocytes were harvested,
puriﬁed, and irradiated (1,500 Rad). The 5  10
5 recipient splenocytes were
incubated with 5  10
5 irradiated Balb/C splenocytes in RPMI medium
supplemented with 10% FCS (Invitrogen) for 48 h (ELISPOT) or 96 h (mixed
lymphocyte reaction [MLR]).
ELISPOT. After the incubation period, IFN- ELISPOT plates were washed
and processed according to the manufacturer’s protocols (Ebioscience).
MLR. After the culture period, cells were pulsed for an additional 18 h with 1
Ci
3H thymidine/well and harvested, and thymidine incorporation was
determined using a scintillation counter. For both experiments, splenocytes
from individual transplanted animals in each experimental group were ana-
lyzed in triplicate. Also, for both MLR and ELISPOT assays, wells containing
splenocytes from each treatment group, as well as irradiated target cells, were
analyzed as negative control samples to rule out any nonspeciﬁc proliferation
or IFN production.
Statistical analysis. All statistical analyses in this study were carried out
using SigmaPlot 10 and SigmaStat 3.5 (Systat, Inc.), and results are expressed
as mean  SEM. Mann-Whitney rank-sum tests and ANOVA with Bonferroni
post hoc analysis were used to analyze multiple groups. Kaplan-Meier survival
analyses were compared using the log-rank test.
RESULTS
Combination of EP1013 and CTLA4-Ig results in
long-term islet allograft acceptance and operational
tolerance. Initially, fully MHC-mismatched islet allografts
were completed using chemically diabetic recipients, and
treatment with either EP1013 (days 0–10), CTLA4-Ig (days
0, 2, 4, and 6), combination of EP1013 and CTLA4-Ig, or
vehicle (days 0–10) was commenced. As shown in Fig. 1A,
treatment with EP1013 resulted in no prolongation of islet
allograft survival (mean survival time 18.2 days) compared
with vehicle-treated animals (mean survival time 22.8
days, P  NS). CTLA4-Ig monotherapy resulted in pro-
longed graft survival in 40% of the animals (mean survival
time 103.0 days), whereas the addition of EP1013 to
CTLA4-Ig resulted in a signiﬁcant increase in graft survival
(n  16/18 with long-term survival resulting in mean
survival time 180 days post-transplant; P  0.01 vs.
CTLA4-Ig by log-rank).
To further understand the enhanced outcomes using
EP1013CTLA4Ig versus CTLA4-Ig alone, a series of ex-
periments was carried out in animals with long-term graft
function in each group. To test for tolerance, recovery
nephrectomies were performed in recipients with graft
survival 180 days. After 2 days of hyperglycemia, either
same-donor (Balb/C, H2-d) or third-party (C3H; H2-k)
islets were implanted with no additional therapeutic inter-
vention (Fig. 1B). Re-transplantation with Balb/C islets led
to prolonged graft survival in 20–30% of the recipients,
regardless of the initial treatment group. This demon-
strates that true donor-speciﬁc tolerance was only
achieved in a subgroup of the transplant recipients, de-
spite the presence of indeﬁnite graft survival after the
initial transplant (i.e., “operational tolerance”). Implanta-
tion of C3H islets resulted in rejection in all recipients in
both treatment groups, conﬁrming that operational toler-
ance to the initial graft was achieved without compromis-
ing the recipient’s immunological function (Fig. 1B). One
possible explanation for the lack of donor-speciﬁc toler-
ance in this model is the effect of the tissue injury, local
inﬂammation, and graft cell death at the time of and after
the second transplant, which could alter the recipient’s
ability to maintain donor-speciﬁc tolerance. To minimize
these effects, an additional cohort of animals with long-
term islet graft survival were re-transplanted with Balb/C
islets and also treated with a 10-day course of EP1013,
using the same dosing as the initial treatment period. As
shown in Fig. 1B, this intervention did not improve the rate
of donor-speciﬁc tolerance in animals previously treated
with EP1013CTLA4-Ig.
To explore the immune response to these grafts at
this late time point post-transplant, immunoﬂuores-
cence staining for insulin, CD4, or CD8 was completed.
As shown in Fig. 2, histological analysis of grafts
harvested from tolerant animals previously treated with
either CTLA4-Ig alone or EP1013CTLA4-Ig demon-
strated intact islets with very few intragraft CD4
 or
CD8
 cells. Quantiﬁcation of these cells per high-power
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immune inﬁltrate between treatment groups. Thus,
while combination of EP1013 and CTLA4-Ig resulted in
a dramatic increase in islet allograft survival over time,
analysis at this late time point could not explain the
difference in outcomes observed between animals
treated with EP1013CTLA4-Ig versus CTLA4-Ig alone.
Caspase inhibitor therapy (EP1013) alters early al-
logeneic immune responses. To characterize the im-
pact of EP1013 on the allogeneic immune response in
this model, ex vivo analysis was conducted at an early
time point post-transplant, 1 day after the ﬁnal treat-
ment (day 11 post-transplant). As shown in Fig. 3A,
co-incubation with either donor type or third-party
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FIG. 1. EP1013 therapy, when combined with costimulation blockade using CTLA4-Ig, results in long-term islet graft survival and operational
tolerance. A: Islet allografts were completed across a complete MHC mismatch using Balb/C (H-2d) donors and chemically diabetic B6 (H-2b)
recipients. Caspase inhibitor therapy (EP1013) did not prolong graft survival compared with vehicle-treated animals. Monotherapy with
CTLA4-Ig prevented graft rejection in 40% of recipients, whereas combination of EP1013 and CTLA4-Ig resulted in graft survival of >200 days
in 89% of recipients (P < 0.01 vs. CTLA4-Ig). B: To test for donor-speciﬁc tolerance, graft-bearing kidneys were removed, and animals were
re-transplanted with either donor-type (Balb/C) or third-party (C3H, H-2k) islets without further treatment or with a second 10-day course of
EP1013. When using Balb/C islets, donor-speciﬁc tolerance was demonstrated in 	30% of the transplant recipients (either CTL4-Ig or
CTLA4-IgEP1013 cohorts). Re-transplantation with third-party islets resulted in robust rejection in all recipients.
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in splenocytes harvested from vehicle-treated animals,
which was signiﬁcantly higher than all other treat-
ment groups (P  0.05 by ANOVA). Splenocytes har-
vested from recipients treated with CTLA4-Ig or
EP1013CTLA4-Ig exhibited a markedly reduced prolif-
eration, which was comparable to that observed in naïve
B6 animals. Interestingly, splenocytes harvested from
animals treated with EP1013 monotherapy also dis-
played a markedly reduced proliferation compared with
vehicle-treated animals (P  0.05 by ANOVA).
Similar results were obtained using IFN- ELISPOT to
analyze allo-speciﬁc immune responses (Fig. 3B). In these
assays, splenocytes harvested from vehicle-treated ani-
mals generated a large number of IFN
 spots when
exposed to donor-type stimulators (P  0.05 vs. all other
groups by ANOVA), while co-incubation with third-party
stimulators resulted in a response that was similar to naïve
B6 splenocytes. Splenocytes harvested from animals
treated with CTLA4-Ig or EP1013CTLA4-Ig generated
few IFN spots when exposed to either donor-type or
third-party stimulators, and no difference was observed
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FIG. 2. Allogeneic islet grafts harvested from tolerant animals >150 days post-transplant exhibit minimal immune inﬁltrate and intact islets.
Renal subcapsular islet grafts were harvested from animals surviving >150 days after receiving CTLA4-Ig monotherapy or CTLA4-Ig/EP1013
combination therapy. A: Cryosections of islet grafts were co-stained for insulin (TRITC; red) and either CD4 (FITC, green; left panels)o rC D 8
(FITC; right panels). DAPI nuclear stain (blue) was used to identify all cells present on the section. Representative slides from both treatment
groups are shown at 200 magniﬁcation and demonstrate that the transplanted islets were largely intact with no invasive immune inﬁltrate and
rare CD4
 or CD8
 lymphocytes. B: Quantiﬁcation of CD4 and CD8 staining conﬁrmed that CD4
 and CD8
 lymphocytes were infrequently
observed within the sections, regardless of the initial treatment intervention. For these data, n  10 sections from >5 islet grafts per group were
blinded and subsequently analyzed. (A high-quality digital color representation of this ﬁugre is available in the online issue.)
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B6 splenocytes. Of note, splenocytes harvested from ani-
mals treated with EP1013 monotherapy also displayed a
marked reduction in IFN
 spots after exposure to donor-
type stimulators, as compared with splenocytes harvested
from vehicle-treated animals (P  0.001 by ANOVA).
Immunoﬂuorescence staining of sections cut from the
islet grafts harvested at this early time point was com-
pleted to characterize the relative contribution of different
T-cell subsets to the allogeneic immune response in each
treatment group (Fig. 4). Sections were co-stained for
insulin and CD4, CD8, or Foxp3, and the immunological
markers were quantiﬁed per HPF. Representative tissue
sections demonstrate that treatment with either CTLA4-Ig
(155.0  15.5 cells/HPF, Fig. 4G) or EP1013CTLA4-Ig
(93.5  14.2 cells/HPF, Fig. 4J) resulted in a 50–70%
decrease in CD4
 T-cell inﬁltration compared with vehi-
cle-treated controls (299.8  26.8 CD4
 cells/HPF, Fig. 4A;
P  0.01 by ANOVA). Similar results were observed when
CD8
 staining was quantiﬁed, with both CTLA4-Ig
(134.5  11.9 cells/HPF, Fig. 4H) and EP1013CTLA4-Ig
(162.0  21.8 cells/HPF, Fig. 4K) treatment groups exhib-
iting a nearly 50% decrease in CD8
 T-cell inﬁltration
compared with vehicle-treated animals (279.8  39.7, Fig.
4B; P  0.01 by ANOVA). No signiﬁcant difference in either
CD4
 or CD8
 inﬁltration was observed between animals
treated with EP1013 (237.3  37.9 CD4
 cells/HPF, Fig.
4D, and 200.0  43.5 CD8
 cells/HPF, Fig. 4E) when
compared with vehicle-treated animals.
Quantiﬁcation of regulatory T-cell (Treg) inﬁltration was
carried out using the marker Foxp3 (17). Grafts harvested
from vehicle-treated animals exhibited almost no intra-
graft Foxp3
 Treg cells (5.7  1.7 cells/HPF, Fig. 4C),
which was similar to that observed in animals treated with
CTLA4-Ig (12.3  3.9 cells/HPF, Fig. 4I). In contrast,
treatment with EP1013, either alone (87.8  27.8 cells/
HPF, Fig. 4F) or in combination with CTLA4-Ig (41.0  8.9
cells/HPF, Fig. 4L), resulted in a 7- to 15-fold increase in
the frequency of intragraft Foxp3
 Treg cells (P  0.01 for
each vs. control by ANOVA).
EP1013 therapy prevents allosensitization after islet
transplantation. Development of alloantibodies and do-
nor-speciﬁc sensitization is increasingly being recognized
as an important prognostic factor in long-term allograft
survival (18). To understand the effect of caspase inhibitor
therapy on the B-cell compartment during the allogeneic
immune response, both IgM and IgG alloantibodies were
measured prospectively post-transplant using a cellular
ELISA (16). Vehicle-treated animals generate a robust IgM
(Fig. 5A) and IgG (Fig. 5B) donor-speciﬁc alloantibody
response. Treatment with EP1013, CTLA4-Ig, or EP1013
CTLA4-Ig prevented the formation of either IgM or IgG
alloantibodies over time, even after the discontinuation of
treatment at day 10 (P  0.02 for all treatment groups
versus control for IgM, P  0.05 vs. control for all
treatment groups for IgG, ANOVA). Of note, naïve B6
serum demonstrated a consistent mean optical density of
0.30  0.09 for IgM and a mean optical density of 0.19 
0.07 for IgG, which is statistically signiﬁcant only when
compared with control transplant mice at 2 and 4 weeks
post-transplant. Thus, treatment with either EP1013 or
CTLA4-Ig prevents allosensitization post-transplant in this
model.
DISCUSSION
The present study demonstrates for the ﬁrst time that
combination of EP1013, a selective pan-caspase inhibitor
therapy with CTLA4-Ig, a selective immunomodulatory
therapy, results in long-term islet allograft acceptance.
This approach had a global effect on the allogeneic im-
mune response, as shown by experiments evaluating both
T- and B-cell compartments. EP1013CTLA4-Ig reduced
the frequency of intragraft CD4
 and CD8
 T-cells both in
the short term (Fig. 4) and over time (Fig. 2), and it
reduced the functional alloreactive T-cell response, both
in production of IFN-–secreting allo-speciﬁc lymphocytes
and overall allo-stimulated T-cell proliferation (Fig. 3).
Moreover, this combined approach reduced B-cell allosen-
sitization (Fig. 5). Of note, the immunomodulatory effects
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FIG. 3. EP1013 therapy inhibits early allogeneic T-cell responses, both
as a monotherapy and in combination with CTLA4-Ig. Transplanted
animals were sacriﬁced on day 11 post-transplant for ex vivo immune
analysis using MLR and IFN- ELISPOT assays to measure the alloge-
neic immune response. A: MLR assays revealed that splenocytes har-
vested from vehicle-treated (“control”) recipients reacted with a
nearly twofold increase in proliferation to both donor and third-party
stimulators as compared with naïve animals (P < 0.05). In contrast,
splenocytes harvested with animals treated with EP1013, CTLA4-Ig, or
EP1013CTLA4-Ig proliferated at rates that were comparable to naïve
animals, irrespective of the stimulator source (P < 0.05 vs. control for
all treatment groups). B: IFN- ELISPOT assays demonstrated that
splenocytes from vehicle-treated control animals mounted a robust
donor-speciﬁc allogeneic IFN- response, with a signiﬁcant increase in
number of spots compared with naïve animals (P < 0.05 by ANOVA).
Prior treatment with EP1013, CTLA4-Ig, or EP1013CTLA4-Ig mark-
edly reduced the number of IFN-–secreting alloreactive splenocytes,
to levels comparable to those observed in naïve animals (P < 0.05 for
each treatment group vs. control by ANOVA). For these assays, n  3–4
animals per treatment group were analyzed in triplicate in two sepa-
rate experiments.
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FIG. 4. Histological analysis in the early post-transplant period demonstrates that EP1013 therapy promotes intragraft accumulation of Foxp3

lymphocytes. Animals were sacriﬁced on day 11 post-transplant, and graft-bearing kidneys were harvested for immunﬂuorescent quantiﬁcation
of intragraft lymphocytic inﬁltrates. Insulin staining was used to identify transplanted islets (TRITC; red), and the immune markers CD4 (left
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cells present within the sections, which are shown at 100 (CD4, CD8) or 200 (Foxp3). Representative sections from each treatment group are
shown. M: Quantiﬁcation of CD4, CD8, and Foxp3 staining was conducted in sections from each treatment group. A signiﬁcant reduction in the
number of CD4
 cells/HPF was observed after treatment with CTLA4-Ig or EP1013CTLA4-Ig compared with vehicle (P < 0.01 vs. control for
CASPASE INHIBITOR THERAPY AND ISLET ALLOGRAFT SURVIVAL
1474 DIABETES, VOL. 59, JUNE 2010 diabetes.diabetesjournals.orgof combination of EP1013CTL4-Ig far exceeded the short
treatment period post-transplant, without further require-
ments for immunosuppression. Taken together, these data
indicate that prevention of donor tissue apoptosis using
caspase inhibitor therapy during the engraftment period
can dramatically lower the threshold for anti-rejection
therapy, such that brief treatment with the costimulation
blockade agent CTLA4-Ig results in robust indeﬁnite islet
allograft survival.
In the setting of islet transplantation, a signiﬁcant frac-
tion of the transplanted islets fail to engraft, resulting in a
large requirement for donor tissue and ultimately a ﬂood
of alloantigen during the post-transplant period. Our group
has proven that caspase inhibitor therapy protects islets
during the engraftment period and thus minimizes the total
number of islets required to reverse diabetes (8,9). From
these previous experiments, it is clear that intragraft
apoptosis is markedly reduced, demonstrating the antici-
pated cytoprotective effect of caspase inhibitor therapy on
the graft. However, data in the present study illustrate
another potential beneﬁcial effect of caspase inhibitor
therapy—modulation of the allogeneic immune response.
Previous data in other experimental models have sug-
gested that caspase inhibitors can alter the function of
lymphocytes. In vitro studies have shown that caspase
inhibitors can have a negative regulatory effect on the
immune system, given that caspases play a critical role in
cell cycle regulation of lymphocyte populations (19–21).
Studies using a pan caspase inhibitor (zVAD) on human
lymphocytes demonstrated that this agent potently sup-
pressed lymphocyte proliferation; recall antigen response;
the upregulation of MHC-II, CD25, and CD69; and IL-2
production after stimulation (19). However, conﬁrming
these effects in vivo has been more elusive (22,23). Data in
the present study clearly indicate that caspase inhibitor
therapy strikingly increases the frequency of intragraft
Treg cells, while at the same time reducing the frequency
of alloreactive IFN-–secreting lymphocytes (Figs. 3 and
4). Whether this effect is the result of enhanced prolifera-
tion or a lower threshold for activation selectively within
these key populations is not clear and is on an ongoing
area of research in our lab. Despite clear differences in
intragraft T-cell populations and alloreactive T-cell re-
sponses ex vivo (Figs. 3 and 4), no functional difference in
graft survival was observed using EP1013 monotherapy in
the traditional allograft model (Fig. 1). It is likely that the
multiple noxious stimuli surrounding the transplant pro-
cedure (anesthesia, surgical manipulation, stress-induced
cytokines, etc.) provide too much nonspeciﬁc immune
stimulation and thus limit the effectiveness of EP1013
monotherapy as an immunomodulatory agent. Thus, while
the mechanism of caspase inhibitor–mediated immuno-
modulation is complex, it is evident from data in this study
that a brief post-transplant therapeutic period is of marked
beneﬁt in transplantation.
With regard to tolerance, our data suggest that the
combination of a potent cytoprotective agent (EP1013)
with a selective immunomodulator (CTLA4-Ig) promotes a
state of immunological “ignorance,” where the immune
system is in a state of passive “tolerance” to the graft,
versus mounting an ongoing and reproducible state of
active donor-speciﬁc tolerance. It may be that early up-
regulation of regulatory T-cells promotes this type of
“operational tolerance,” which could explain the observa-
tions in this study, especially given the almost complete
absence of lymphocytes within the graft at late time points
(Fig. 2) versus ﬁndings at an early time point (Fig. 4).
Similarly, the lack of allospeciﬁc IFN- production in
animals treated with EP1013 (Fig. 3B) supports this the-
both groups). Similar results were observed for CD8
 cells/HPF, with CTLA4-Ig or EP1013CTLA4-Ig treatment cohorts exhibiting a signiﬁcant
decrease compared with vehicle-treated animals (P < 0.01 vs. control for both groups). Quantiﬁcation of Foxp3
 cells/HPF revealed that prior
treatment with EP1013, either alone or in combination with CTLA4-Ig, resulted in a signiﬁcant increase in the frequency of intragraft regulatory
T-cells (P < 0.01 vs. control and vs. CTLA4-Ig alone by ANOVA). Serial tissue sections from n  3–4 animals per group were stained, blinded, and
analyzed for this experiment. (A high-quality digital color representation of this ﬁgure is available in the online issue.)
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FIG. 5. EP1013 therapy prevents both IgM and IgG alloantibody
formation, both as a single agent and in combination with CTLA4-Ig.
Sera were collected via tail vein bleeds prospectively and stored for
bulk analysis at the completion of the study using a donor-speciﬁc
cellular ELISA to measure alloantibody production. A: IgM alloanti-
body formation was detected in vehicle-treated control animals (F),
while treatment with EP1013 (E), CTLA4-Ig (Œ), or EP1013CTLA4-Ig
(‚) resulted in a signiﬁcant reduction in IgM alloantibody formation
(P < 0.02 for all treatment groups vs. control). B: Similar results were
obtained when IgG alloantibody levels were assessed, with vehicle-
treated control animals becoming highly sensitized within 2 weeks
post-transplantation (F). IgG allosensitization was prevented after
treatment with EP1013 (E), CTLA4-Ig (Œ), or EP1013CTLA4-Ig (‚)
(P < 0.05 for each treatment group vs. control). A minimum of n  5
serum samples from each treatment group were analyzed in duplicate
for these assays. OD, optical density.
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important component of donor-speciﬁc tolerance induc-
tion (24).
The present study was conducted using islet allograft
transplantation, and our results indicate that this approach
could be of particular beneﬁt in the clinical setting. Brief
treatment with caspase inhibitors can minimize the
amount of donor tissue required to restore euglycemia by
as much as 80%, thereby increasing the “transplantability”
of high-quality clinical islet preparations of low yield by
current standards (300,000 islet equivalents) (8,25).
Whereas true donor-speciﬁc tolerance was not universally
achieved in our study, our data strongly suggest that this
approach will reduce the intensity and/or duration of
immunosuppression required, which would still represent
a major advance in the ﬁeld. Another important consider-
ation is the lack of donor sensitization in this model, which
has recently been identiﬁed as a potential cause of chronic
graft failure in clinical islet transplantation (26,27). Previ-
ous studies have shown that costimulation blockade can
prevent allo-sensitization post-transplant (28). Our data
support these ﬁndings and demonstrate that combination
therapy with EP1013 does not reduce the efﬁcacy of
CTLA4-Ig in this regard.
While this study was limited to islet allograft transplan-
tation, it is likely that the combined use of caspase
inhibitors and costimulation blockade will be of beneﬁt in
all areas of solid organ transplantation. As the demand for
organs continues to outpace donation rates worldwide, it
has increasingly become the trend to use organs procured
from extended criteria donors or even after donation after
cardiac death. Use of extended criteria donor and dona-
tion after cardiac death organs increases the rate of
delayed graft function and reduces long-term graft survival
rates (29). The inclusion of a caspase inhibitor in the
preservation solution in a murine model of acute kidney
injury dramatically reduced renal tubular apoptosis and
brush border injury, two processes that have been linked
to delayed graft function (30). Similar results have been
obtained in a cardiac allograft model, where early treat-
ment with a caspase inhibitor reduced intimal prolifera-
tion and vessel occlusion, which are both important
markers of chronic allograft vasculopathy (31). Thus, it is
likely that the cytoprotective beneﬁts of caspase inhibitor
therapy combined with selective nontoxic immunosup-
pression using costimulation blockade will broadly im-
prove both graft function and long-term survival in many
areas of organ transplantation.
In summary, data in this study indicate that caspase
inhibitors represent the ﬁrst single agent therapy that has
the potential to beneﬁt the graft directly, while also
regulating the allogeneic immune response. Caspase inhib-
itors have been used clinically in liver transplantation and
so far have proven to be safe and effective in improving
graft function post-transplant (32–34). It is likely that
inclusion of caspase inhibitors in clinical transplantation
protocols will be of greatest beneﬁt in situations where
considerable stress to the donor organ is generated, par-
ticularly after the process of brain death, prolonged isch-
emic time, or use of extended criteria donors. It is also
likely that this approach will reduce the amount and
intensity of anti-rejection therapy, accelerating accommo-
dation and drug minimization. If this could be achieved, or
if the stable immunological tolerance enhanced by caspase
inhibitor co-treatment could be translated to the clinic,
transplantation would be potentially safer and therefore
more available to a broader spectrum of patients.
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